Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
J Cancer Res Ther ; 2020 May; 16(2): 393-396
Artigo | IMSEAR | ID: sea-213830

RESUMO

We present a case of Robo1‑specific chimeric antigen receptor natural killer (CAR‑NK) cell therapy for pancreatic ductal adenocarcinomawith liver metastasis in a 46‑year‑old male. The patient was treated with Robo1‑specific CAR‑NK cell infusion. Liver metastasis wastreated with percutaneous Robo1‑specific CAR‑NK Cell injection. In the 1st month, the patient received Robo1‑CAR‑NK intravenousinjection on days 1 and 3 and percutaneous injection on days 2 and 4 every week, respectively, and the dosage administered was1×109 Robo1‑ specific CAR‑NK cell, respectively. The patient continuously received Robo1‑CAR‑NK intravenous injection once aweek. An evaluation was conducted every 2 weeks. The patient was safely applied the therapy with no substantial adverse effects.Pancreatic lesion was controlled within 5 months. Karnofsky Performance Score and child stage of the patient did not change greatlyduring the therapy, and the patient’s overall survival time was 8 months

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA